BrainsWay OCD Represents A Significant Transformation in OCD Treatment

Only platform TMS technology, enabling treatment of multiple indications, including MDD and OCD
- First non-invasive, novel FDA-cleared medical therapy for OCD in over a decade (FDA De Novo No. DEN170078)
- The depth and breadth of BrainsWay's H-coil technology enables targeting of multiple treatment areas

Current treatment methods are ineffective for a large segment of patients*
- Over 2 million adults are diagnosed with OCD each year. Approximately 50% of OCD patients are resistant to current first-line treatment methods, including CBT and SSRI medications

Many patients cannot tolerate medication side effects
- Patients often discontinue SSRIs due to debilitating side effects, such as weight gain, sexual dysfunction, suicidal thoughts, nausea, insomnia, and anxiety

Large-scale, double-blinded multicenter RCT submitted to FDA demonstrates BrainsWay OCD treatment safe & effective

> 1 in 3 patients achieved over 30% reduction in Y-BOCS
> 1 in 2 patients achieved over 20% reduction in Y-BOCS

- Response was achieved among patients who did not experience relief from SSRIs or psychotherapy
- Number Needed to Treat (NNT) of 3.7 after 6 weeks of treatment
- Low drop-out rate of 10.6%

> 6.7 mean change in Y-BOCS from baseline achieved after 6 weeks
> Improved CGI-I score maintained at week 10

Patients remained on existing maintenance CBT and SSRI medications.
Treatment consists of 5 sessions per week for 6 weeks, with a tailored provocation protocol during each session.

contact@brainsway-usa.com
www.brainsway.com